PORTEFEUILLE

DIATHERIS is a spin-off of the University of Geneva with the goal of developing a groundbreaking therapeutic solution to improve the treatment of type 1 diabetes. Currently, insulin therapy stands as the sole option for type 1 diabetes (T1D) patients. However, this therapy has proven suboptimal, with a central challenge being the achievement of proper glycemic control without the associated risks of life-threatening hypoglycemia and ketoacidosis. Additionally, the lipogenic action of therapeutic insulin contributes to overweight, a significant factor in cardiovascular co-morbidities among T1D patients.
The existing strategies to enhance insulin therapy for T1D fall short of providing a satisfactory solution. While adjunct therapies improve hyperglycemia, they concurrently elevate the risk of life-threatening hypoglycemia and ketoacidosis—persistent challenges in T1D treatments. At Diatheris, we are actively developing a first-in-class therapeutic solution to overcome these limitations and enhance T1D management.
Our proprietary approach hinges on a small protein known as S100A9. The S100A9 treatment exploits an insulin-independent pathway, displaying remarkable results in combination with low-dose insulin. This combination works to improve glycemic control, effectively normalizing glycemia without the associated risks of hypoglycemia and ketoacidosis.

The Innobooster program is instrumental in developing a final drug formulation, enabling the initiation of regulatory toxicology studies necessary for a first-in-human clinical trial application.